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Francisella tularensis is a Gram-negative coccobacillus and is the etiological agent of the disease tularemia. Expression of the cy-
toplasmic membrane protein RipA is required for Francisella replication within macrophages and other cell types; however, the
function of this protein remains unknown. RipA is conserved among all sequenced Francisella species, and RipA-like proteins
are present in a number of individual strains of a wide variety of species scattered throughout the prokaryotic kingdom. Cross-
linking studies revealed that RipA forms homoligomers. Using a panel of RipA-green fluorescent protein and RipA-PhoA fusion
constructs, we determined that RipA has a unique topology within the cytoplasmic membrane, with the N and C termini in the
cytoplasm and periplasm, respectively. RipA has two significant cytoplasmic domains, one composed roughly of amino acids 1 to
50 and the second flanked by the second and third transmembrane domains and comprising amino acids 104 to 152. RipA func-
tional domains were identified by measuring the effects of deletion mutations, amino acid substitution mutations, and sponta-
neously arising intragenic suppressor mutations on intracellular replication, induction of interleukin-1 (IL-1) secretion by
infected macrophages, and oligomer formation. Results from these experiments demonstrated that each of the cytoplasmic do-
mains and specific amino acids within these domains are required for RipA function.
Francisella tularensis is a Gram-negative coccobacillus that is theetiological agent of the zoonotic disease tularemia. F. tularensis
infects a wide range of hosts, which includes humans, but pre-
dominately infects small mammals such as rabbits, voles, and
squirrels (24). F. tularensis has been isolated from arthropod vec-
tors such as ticks (29, 34), mosquitoes (28, 43), and deerflies (24),
which are also a source of transmission to humans (5, 6). Addi-
tional modes of transmission to humans include contact with in-
fected animals (30, 31, 36), ingestion of contaminated food or
water (23, 25), and inhalation of aerosolized bacteria (37, 42).
There are four main subspecies of F. tularensis that differ in their
virulence for humans: F. tularensis subsp. novicida, mediasiatica,
holarctica, and tularensis. F. tularensis subsp. novicida is not gen-
erally considered pathogenic for humans; however, there have
been a few cases reported (1, 9, 20, 26). F. tularensis subsp. media-
siatica is associated with human disease in Asia, though less is
understood about its pathogenesis (24). F. tularensis subsp. holar-
ctica and tularensis are most commonly associated with disease in
humans, with the latter being associated with the lowest infectious
dose and most severe disease. For F. tularensis subsp. tularensis,
transmission to humans via the inhalational route can occur at an
infectious dose of as few as 10 organisms (35). The ease of aero-
solization and low infectious dose resulted in the designation of F.
tularensis subsp. tularensis a select agent by the Centers for Disease
Control and Prevention (CDC), especially considering the histor-
ical development of F. tularensis bioweapons by several countries
during the Cold War (13).
Within the lung, F. tularensis travels to the alveoli, where it
infects a wide range of cell types, including alveolar macrophages,
neutrophils, dendritic cells, monocytes, and alveolar type II epi-
thelial cells (2, 18, 19). F. tularensis is taken up by host cells via
looping phagocytosis, and after internalization, the bacteria es-
cape the phagosome to replicate to high numbers in the cytoplasm
(10, 11). In addition to the ability to replicate intracellularly, F.
tularensis has the ability to suppress the proinflammatory immune
response (2, 3, 8, 22, 40, 41). Several F. tularensis proteins have
been reported as virulence factors that are required for this intra-
cellular life cycle; however, many of the identified virulence factors
have little or no similarity to known proteins of other bacteria and
their functions remain, for the most part, unknown.
Previously we identified a locus called ripA that is required for
F. tularensis virulence. More specifically, deletion of this locus in
the live vaccine strain (LVS) resulted in a mutant (LVSripA) that
escapes the phagosome but is defective for intracellular replication
(17) and fails to suppress the proinflammatory immune response
(22). Not surprisingly, LVSripA is also attenuated in a pulmo-
nary mouse model of tularemia (17). Deletion of ripA in the highly
virulent strain F. tularensis Schu S4 results in a mutant that is
defective for intracellular replication and attenuated in a mouse
model as well, suggesting that RipA is required for virulence in
highly pathogenic F. tularensis subsp. tularensis (our unpublished
results).
RipA is a cytoplasmic membrane protein that is conserved
among Francisella species (17). Interestingly, bioinformatic anal-
yses show that there is sporadic representation of RipA-like pro-
teins among prokaryotes, where RipA-like proteins are found in
only specific strains of a given bacterial species. Similar to RipA,
these other proteins are annotated as hypothetical proteins with
no known functions or conserved domains; thus, the function of
RipA remains unknown. RipA is a small protein (17 kDa) with
three putative transmembrane domains and has a single cysteine
found within the second membrane-spanning domain, which are
unusual properties for a membrane protein, and examples of sim-
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ilar proteins in the literature are sparse. The unusual biochemical
properties of RipA, combined with its random distribution but
obvious conservation within prokaryotes, led us to study RipA for
its potential to provide insight into what may be a novel class of
proteins and/or to reveal a novel virulence mechanism employed
by F. tularensis.
In this study, we addressed the question of RipA function by
analyzing RipA at the biochemical and molecular levels. Our re-
sults confirm a predicted topology model of RipA in the cytoplas-
mic membrane and show that RipA forms homoligomers. Using
the topology model and alignments with other RipA-like proteins,
we generated amino acid substitutions at conserved amino acids
and deleted the two individual cytoplasmic domains within RipA.
We analyzed these amino acid substitution and domain deletion
mutants for the abilities to replicate intracellularly, suppress the
immune response, and form RipA oligomers. We also identified
and analyzed an intragenic suppressor mutant. Using the suppres-
sor mutant as well as the substitution and deletion mutants of
RipA, we showed that both cytoplasmic domains and at least four
amino acids are required for RipA function.
MATERIALS AND METHODS
Bacterial strains. F. tularensis subsp. holarctica LVS was obtained from
the CDC, Atlanta, GA. All Francisella strains were maintained on choco-
late agar supplemented with 1% IsoVitaleX (BD) and, when applicable, 10
g ml1 kanamycin (Kan10) for selection. For growth of bacteria for
infection or monitoring of in vitro growth, strains were propagated in
Chamberlain’s defined medium (CDM) (7). Escherichia coli TOP10 (In-
vitrogen) or DH10b (Invitrogen) was used for cloning. E. coli CC118 or
BL21(DE3)pLysS was used for the expression of topology fusion reporter
proteins. E. coli was propagated in Luria broth (LB) supplemented with
ampicillin at 100 g ml1 (Amp100) or kanamycin at 50 g ml1
(Kan50), as necessary for antibiotic selection. All cultures were grown at
37°C with aeration.
Cell culture. TC-1 (ATCC CRL-2785) cells are a tumor cell line de-
rived from mouse primary lung epithelial cells and were cultured in RPMI
1640 medium supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, 1.5 g liter1 sodium bicarbonate, 10 mM HEPES, and 0.1
mM nonessential amino acids. J774A.1 (ATCC TIB-67) cells are a
macrophage-like cell line derived from mouse sarcoma reticulum cells
and were cultured in Dulbecco’s minimal essential medium with 4.5 g
liter1 glucose, 10% fetal bovine serum, and 2 mM L-glutamine. Bone
marrow-derived macrophages (BMMs) were generated by flushing
C57BL/6 mouse femurs, and recovered cells were incubated for 6 days on
15-cm2 non-tissue-culture-treated dishes in L929 cell-conditioned Dul-
becco’s modified Eagle’s medium (DMEM). Nonadherent cells were re-
moved by washing with phosphate-buffered saline (PBS), and BMMs
were recovered from the dishes using 10 mM EDTA in PBS. For experi-
ments, BMMs were maintained in DMEM plus 10% FBS.
Molecular techniques and mutagenesis. To generate constructs for
RipA fusion protein expression using the Phusion polymerase (New Eng-
land Biosciences), we PCR amplified ripA from LVS genomic DNA using
primers that introduced XhoI and BamHI restriction sites directly before
the start codon and in place of the stop codon of ripA, respectively. For
cloning of truncated ripA constructs, the reverse primer introduced a
BamHI restriction site at the respective locations in the ripA sequence but
used the same forward primer. These constructs were first cloned into the
pCR-Blunt II TOPO vector (Invitrogen) and subsequently subcloned us-
ing BamHI and XhoI restriction digestion and ligation into pWaldo-TEV-
GFPe and pHA-4 (33) to generate the fusion protein expression con-
structs. For expression of fusion proteins, the plasmids were transformed
into E. coli CC118 (pHA-4) or E. coli BL21(DE3)pLysS (pGFPe) by elec-
troporation with selection on ampicillin at 100 g ml1 (pHA-4) or
kanamycin at 50 g ml1 (pGFPe).
The cytoplasmic loop deletions in ripA were generated by gene syn-
thesis of ripA containing the designated nucleotide deletions (corre-
sponding to amino acids 4 to 47 or 105 to 151) and linker sequence inser-
tion while maintaining the integrity of the flanking regions (Blue Heron).
Each construct was PCR amplified from the synthesis vector and cloned
into the pCR-Blunt II TOPO vector (Invitrogen), verified by DNA se-
quence analysis, and subsequently subcloned into pMP590 (sacB Kanr)
using the BamHI and NotI restriction sites (27). For allelic exchange,
plasmids were electroporated into LVS and integrants were selected on
chocolate agar containing kanamycin (10 g ml1). Kanr strains were
grown overnight and plated on 10% sucrose for counterselection (loss of
plasmid) (17). Deletions were confirmed by PCR analysis of genomic
DNA using primers external to the deleted regions. The strategy for gen-
eration of the ripA deletion in LVS and for complementation of the ripA
deletion has been described previously (17).
Single amino acid changes in RipA were generated by introducing 1-
or 2-bp changes into the respective codon of the ripA DNA sequence using
a QuikChange II site-directed mutagenesis kit (Stratagene) and following
the manufacturer’s protocol. The plasmid used for mutagenesis was the
multicopy Francisella shuttle vector pKKMCS, which expressed ripA un-
der the control of its native promoter and containing both 5= and 3=
flanking regions. After DNA sequence confirmation of the mutations
within ripA, the plasmids were each transformed into the LVSripA strain
by electroporation and selection on chocolate agar with Kan10.
To generate hemagglutinin (HA)-tagged ripA, a fusion construct was
made by splice overlap extension PCR (21) with primers that introduced
the HA tag in frame into the C terminus of the coding sequence of ripA
and including a glycine linker sequence between the end of the coding
sequence and the HA tag. This construct was sequenced before use, cloned
into the pMP590 suicide vector, and then used for allelic exchange to
generate a chromosomally expressed, HA-tagged protein. Clones were
screened using one primer specific to the tag and the second specific to a
sequence on the chromosome. Additionally, this same construct was
cloned into pKKMCS to generate a plasmid-expressed, HA-tagged pro-
tein. The integrity of the sequence was confirmed by DNA sequence anal-
ysis.
Green fluorescent protein (GFP) fluorescence and alkaline phos-
phatase activity assays. Procedures for protein expression, GFP fluores-
cence, and PhoA activity were adapted from previously published proto-
cols (12, 15, 33). For the expression of GFP fusion proteins, E. coli
BL21(DE3)pLysS containing each construct was grown in 1 ml LB–Kan50
overnight at 37°C and then diluted 1:50 into 500 l LB–Kan50 per well of
a 48-well plate and grown at 37°C and 250 rpm to an optical density at 600
nm (OD600) of 0.3 to 0.4. Expression was then induced by the addition of
0.4 mM isopropyl--D-thiogalactopyranoside (IPTG), and cultures were
grown to a final OD600 of 0.6 to 0.8. Cell pellets were resuspended in 200 l
of buffer containing 50 mM Tris-HCl (pH 8.0), 200 mM NaCl, and 15
mM EDTA and incubated for 30 min at room temperature. Samples were
then transferred to a black 96-well plate (Nunclone) and analyzed for GFP
fluorescence using a 485-nm excitation filter, a 512-nm emission filter,
and a cutoff of 495 nm with the TECAN Infinite M200 and analyzed using
Magellan v6 software. For calculated GFP fluorescence, after subtraction
of the cell background fluorescence, GFP emission was normalized
against the OD600 of the culture.
For expression of the PhoA fusion proteins, E. coli CC118 with each
construct was grown in 1 ml LB–Amp100 overnight at 37°C and then
diluted 1:50 into 500 l LB–Amp100 per well of a 48-well plate and grown
at 37°C and 250 rpm to an OD600 of 0.13 to 0.18. Arabinose was added to
a final concentration of 0.2%, and bacteria were grown to an OD600 of 0.3
to 0.6. To prevent spontaneous PhoA activation, 1 mM iodoacetamide
was added 10 min prior to harvesting and to all subsequent buffers. Sam-
ples were washed once in cold 10 mM Tris-HCl, pH 8.0, containing 10
mM MgSO4 and resuspended in 1 ml cold 1 M Tris-HCl, pH 8.0. Then,
100 l of each sample was added to 900 l of 1 M Tris-HCl, pH 8.0,
containing 1 mM ZnCl2 and an OD600 measurement of the remaining
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sample was made. We next added 50 l of 0.1% SDS and 50 l of chloro-
form, vortexed the mixture for 15 s, incubated it at 37°C for 5 min to
permeabilize the cells, and then placed the mixture on ice for 5 min to cool
it. Finally, we added 100 l of 0.4% p-nitrophenylphosphate (in 1 M
Tris-HCl, pH 8.0) and incubated the mixture at 37°C. The tubes were
monitored until each turned pale yellow, and then 120 l of 1:5 0.5 M
EDTA, pH 8.0, containing 1 M KH2PO4 was added to stop the reaction.
The OD550 and OD420 of each sample were determined, and to calculate
the activity, the following equation was used: Units of activity 
{[OD420  (1.75  OD550)]  1,000}/(time in minutes  OD600  vol-
ume of cells in milliliters).
Protein cross-linking. Overnight cultures of LVS were grown in CDM
(pH 6.3) and either used for cross-linking or reseeded to grow to mid-log
phase (150 Klett units). Each culture was aliquoted into 250- to 500-l
samples, washed once in 1 PBS, and then resuspended in the same
buffer. Cross-linker was added to samples at a final concentration of 0.5%
for formaldehyde or 0.5 mM for dithiobis(succinimidyl propionate)
(DSP). Samples were incubated at room temperature for 30 min. For
DSP-treated samples, 100 mM Tris-HCl (pH 7.4) was added to quench
the reaction. All formaldehyde-treated samples were then washed once in
ice-cold 1 PBS and resuspended in 200 l SDS-PAGE loading buffer
plus -mercaptoethanol (ME) and heated at 60°C for 10 min (to main-
tain cross-linking) or at 100°C for at least 20 min (to cleave cross-linking).
All DSP-treated samples were resuspended in SDS-PAGE buffer without
ME (to maintain cross-linking) or with ME (to cleave cross-linking)
and heated at 100°C for 10 min. All samples were analyzed by SDS-PAGE
and Western blot assay as described below.
Membrane fractionations. LVS was grown overnight in 15-ml cul-
tures in CDM (pH 6.3) at 37°C, pelleted, and washed once in lysis buffer
(150 mM NaCl, 10 mM Tris, pH 7.5). Cells were lysed in Lysis Matrix B
tubes (MP Biomedicals) by beating in a Mini-BeadBeater (Biospec Prod-
ucts) for 45 s twice at 4°C. Cell lysates were collected after the beads settled
and clarified by centrifugation at 12,000  g for 3 min. Crude membrane
fractions were separated from cytoplasmic fractions by ultracentrifuga-
tion at 100,000  g for 90 min, with the cytoplasmic fraction being in the
supernatant. The remaining crude membrane fraction pellet was solubi-
lized in lysis buffer containing a final concentration of 0.5% Sarkosyl and
incubated at room temperature with shaking for 30 min. Insoluble outer
membrane components were isolated from the cytoplasmic membrane
fractions (supernatant) by centrifugation at 100,000  g for 60 min (17).
Protein concentrations in each fraction were determined using a standard
bicinchoninic acid (BCA) assay (Thermo Scientific).
SDS-PAGE and Western blot assay. Either 4 to 20% or 12% Pierce
Precise protein gels (Thermo Scientific) were loaded with the designated
samples at equal concentrations as determined by BCA assay and run
using BupH Tris-HEPES-SDS running buffer at 120 V. To determine
molecular masses, either Benchmark Prestained Protein Ladder (Invitro-
gen) or PageRuler Plus Prestained Ladder (Fermentas) was used. For
Western blot assay, gels were transferred to nitrocellulose membranes at
400 mA for 45 min and then blocked overnight in 1% bovine serum
albumin in PBS–Tween 20 (PBST). All antibodies were incubated at room
temperature with rocking for 1 h with PBST washes between incubations.
The primary antibody used was a rabbit anti-RipAaa1-19, anti-
RipAaa112-128 (both described below), or mouse anti-HA monoclonal
antibody (Sigma), and the secondary antibody used was a goat anti-rabbit
IgG IRDye 680 or goat anti-mouse IgG IRDye 800CW antibody. Protein
was detected by near infrared fluorescence at 700 nm or 800 nm using the
Odyssey Infrared Imaging System (LI-COR Biosciences).
Generation of affinity-purified antibodies against RipA peptides.
Two RipA peptide sequences corresponding to amino acids 1 to 19 and
amino acids 112 to 128 were synthesized by YenZyme Antibodies, LLC,
for the production of each peptide and then rabbit antiserum and affinity
purification of antibodies against each peptide. Preimmune sera were also
collected from the rabbits and used during initial tests of the antibodies for
reactivity and specificity in Western blot assays of LVS lysates.
Gentamicin protection assays. TC-1 epithelial cells or J774A.1 mac-
rophages were inoculated with LVS at a multiplicity of infection (MOI) of
100 after determination of bacterial concentrations in Klett units. All LVS
strains were grown overnight in CDM (pH 6.3) prior to inoculation. The
cells were incubated with the bacterial inoculum for 2 h (J774A.1) or 4 h
(TC-1) and then incubated with medium containing 25 g ml1 genta-
micin for an additional 2 h to kill the extracellular bacteria. At 4 h
(J774A.1) or 6 h (TC-1) postinfection and at 24 h postinfection, medium
was removed, cells were washed with PBS and then scraped from the dish,
and the bacteria were serially diluted and plated to determine the number
of viable bacteria.
IL-1 enzyme-linked immunosorbent assays (ELISAs). BMMs were
prepared as described above and seeded into 12-well dishes at 1  106/well
on the day of infection. At 1 to 2 h after plating, cells were inoculated with
bacteria at an MOI of 500 and incubated at 37°C. After 24 h, the superna-
tants from each well were collected and centrifuged to pellet cellular de-
bris. The IL-1 ELISA was performed using the BD OptEIA mouse IL-1
ELISA kit (BD Biosciences) according to the manufacturer’s protocol.
The OD450 was read using a TECAN Infinite M200 and analyzed using
Magellan v6 software.
Statistical analysis. For intracellular replication assay data, the differ-
ences in total CFU values at the 24-h time point for each strain were
analyzed for significance using the unpaired, two-tailed Student t test. For
IL-1 ELISA data, significance was determined by repeated-measures
one-way analysis of variance with a Dunnett multiple-comparison post-
test. Other details and P values are included in the figure legends. All
statistical values were calculated using GraphPad Prism v.5 software
(GraphPad).
RESULTS
Mapping of RipA topology using carboxyl-terminal fusion re-
porter proteins. RipA is a 179-amino-acid cytoplasmic mem-
brane protein estimated to be approximately 17 kDa (17). Using
the annotated amino acid sequence for RipA and the TMHMM
software (38), the topology of RipA was predicted. The TMHMM-
predicted RipA topology was also supported using several other
prediction programs (data not shown). The data output from
TMHMM was used in TMRPres2D (39) to generate the image
depicted in Fig. 1A. This model predicted that RipA has three
membrane-spanning domains (amino acids 51 to 71, 83 to 103,
and 152 to 172), with the amino terminus (N terminus) in the
cytoplasm and the carboxyl terminus (C terminus) in the
periplasm. Also predicted within RipA are two large cytoplasmic
domains (amino acids 1 to 50 and 104 to 151) and two smaller
periplasmic domains (amino acids 72 to 82 and 173 to 179). It is
rare for a protein to have only three transmembrane domains with
this orientation, and very few such proteins have been thoroughly
characterized (12, 15, 33).
Considering the value of validating such a unique topology for
RipA, we made use of a fusion reporter protein system that has
been used to map E. coli cytoplasmic membrane proteins (12, 15,
33). In this system, either GFP or alkaline phosphatase (PhoA) was
fused at the C-terminal end of recombinant proteins or peptides
and expressed in E. coli, and GFP fluorescence or PhoA activity
was assayed. GFP is only fluorescent in the cytoplasm, and PhoA is
active only in the oxidizing environment of the periplasm (14).
Thus, by fusing GFP or PhoA to a protein, one can determine the
cytoplasmic or periplasmic location of the C terminus of the pro-
tein. GFP or PhoA was fused at the C terminus of RipA and at four
locations predicted to be near transmembrane junctions of RipA,
thereby generating fusion proteins expressing amino acids 1 to 47,
1 to 80, 1 to 106, 1 to 148, and also 1 to 179 (full-length RipA). The
Mortensen et al.
1476 jb.asm.org Journal of Bacteriology
locations on RipA at which the fusions were made are highlighted
in Fig. 1A by the orange arrows. C-terminal fusion proteins of
DcuB and GlpT, two E. coli proteins that have been identified as
having C termini with periplasmic and cytoplasmic locations, re-
spectively, were included as controls (12). The GFP fusion pro-
teins were expressed in E. coli BL21(DE3)pLysS, and PhoA fusion
proteins were expressed in phoA mutant E. coli CC118. The GFP
fluorescence or PhoA activity of each construct was measured and
graphed as the ratio of PhoA to GFP (Fig. 1B). As expected, the
control DcuB fusion protein had a high PhoA-to-GFP ratio, cor-
responding to a periplasmic location, and the control GlpT fusion
protein had a low PhoA-to-GFP ratio, corresponding to a cyto-
plasmic location. In terms of RipA, fusion proteins for amino
acids 1 to 47, 1 to 106, and 1 to 148 had low PhoA-to-GFP ratios
(i.e., high GFP fluorescence), corresponding to a cytoplasmic lo-
cation for RipA at amino acids 47, 106, and 148. Constructs for
amino acids 1 to 80 and 1 to 179 had higher PhoA-to-GFP ratios
(i.e., high PhoA activity), corresponding to a periplasmic location
at amino acids 80 and 179. Thus, the fusion protein reporter sys-
tem supports the idea that the predicted RipA topology is correct.
RipA forms homoligomers, as revealed by in vivo cross-
linking in LVS. It is possible that RipA, as a small, integral cyto-
plasmic membrane protein, interacts with itself and/or other
proteins. Additionally, under nonreducing conditions, higher-
molecular-mass bands have been observed on Western blots
probed with anti-RipAaa1-19 antibody. For example (Fig. 2A),
under nonreducing conditions (i.e., no addition of ME), there
are at least three higher-molecular-mass bands, whereas there is
only one higher-molecular-mass band under reducing condi-
tions. This result hints that RipA may be interacting with itself as a
homoligomer. In order to capture potential RipA oligomerization
in vivo, two different bifunctional, reversible chemical cross-
linkers, formaldehyde and DSP, were used to treat LVS grown in
chemically defined medium. Formaldehyde was added to cells at
concentrations ranging from 0.1 to 1%, and the optimal concen-
tration was found to be 0.5%, which was used for subsequent
experiments. Cleavage of formaldehyde-mediated protein inter-
actions is accomplished by boiling samples. DSP was added to cells
at concentrations ranging from 0.5 to 1 mM, and the optimal
concentration was found to be 0.5 mM, which was used for sub-
sequent experiments. DSP-mediated interactions are reversed by
the addition of ME. Cross-linking with either formaldehyde or
DSP revealed that RipA formed two to four higher-molecular-
mass bands of 40 kDa, 55 kDa, 70 kDa, and sometimes 100 kDa
that disappeared upon cleavage of the cross-linker (Fig. 2B). These
higher-molecular-mass bands likely represent a range of oligo-
meric states of RipA.
To determine whether the higher-molecular-mass complexes
correspond to RipA interacting with itself, as opposed to other
proteins, cross-linking experiments were performed with two
complementary strains: HA-tagged ripA expressed on a plasmid in
wild-type LVS and chromosomally expressed HA-tagged ripA
with wild-type ripA on a plasmid. With each strain, both the native
and HA-tagged RipA proteins were expressed by the ripA pro-
moter on the same multicopy plasmid backbone. Each of these
strains, as well as wild-type LVS, was cross-linked with formalde-
hyde and analyzed via Western blot assay using antibodies against
both RipAaa1-19 and the HA tag. Secondary antibodies conju-
gated to different-wavelength infrared dyes allowed for differen-
tial labeling of native and HA-tagged RipA (RipA-HA), and the
HA tag allowed for differentiation by size. Due to the lower reso-
lution of the higher-molecular-mass bands, we focused on the
40-kDa band that corresponded to a potential RipA dimer. As
expected, in place of a single band, there were three bands differing
by only a few kDa in the two strains containing HA-tagged and
wild-type ripA. The lowest-molecular-mass band corresponds to
RipA/RipA dimers, the middle-molecular-mass band corre-
sponds to RipA/RipA-HA dimers, and the highest-molecular-
mass band corresponds to RipA-HA/RipA-HA dimers (Fig. 2C).
These data suggest that RipA interacts with itself and forms a
homodimer and possibly higher-number homoligomers. Work to
identify whether RipA also interacts with other proteins is under way.
FIG 1 Mapping of RipA within the cytoplasmic membrane using C-terminal
fusion reporter proteins in E. coli. (A) The predicted topology model of RipA
was determined using TMHMM, and the image was made using TMRPres2D.
The yellow tags label the 13 amino acids that are conserved among RipA-like
proteins in other bacterial strains, as well as the single cysteine found within
Francisella RipA. The orange arrows highlight the amino acids at which the
fusion reporter proteins were made. The colors designate electrostatic poten-
tial, with red highlighting negatively charged amino acids and blue highlight-
ing positively charged amino acids. (B) RipA C-terminal fusion proteins were
expressed in E. coli alongside GlpT and DcuB C-terminal fusion proteins as
GFP- and PhoA-positive controls, respectively. Each strain was assayed for
PhoA activity or GFP fluorescence, as appropriate. Data are represented as
PhoA-to-GFP ratios consolidated from at least three experiments for each
construct performed in duplicate or triplicate. Error bars represent the stan-
dard deviations of the composite PhoA-to-GFP ratios from all experiments.
Primary expression data are presented in Table S2 in the supplemental
material.
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The cytoplasmic domains of RipA are important for RipA
function. Having determined the topology of RipA in the cyto-
plasmic membrane, we set out to identify which domains of RipA
are required for function. Since protein-protein interactions often
occur in the cytoplasm and because there are two large domains
within RipA in the cytoplasm, the two cytoplasmic domains were
targeted for analysis as putative functional domains using intra-
cellular replication, induction of IL-1 secretion by infected mac-
rophages, and RipA oligomer formation as functional readouts.
Independent deletion of the domain corresponding to amino ac-
ids 4 to 47 or 105 to 151 was constructed by replacement with a
15-amino-acid linker sequence rich in glycines and serines and
also two prolines for flexibility. This resulted in two LVS mutants
designated LVS ripAaa4-47 and LVS ripAaa105-151. These
mutants were analyzed for intracellular replication in J774A.1
murine macrophages (Fig. 3A) and TC-1 epithelial cells (Fig. 3B).
The results demonstrate that LVS ripAaa4-47 and LVS
ripAaa105-151 are both defective for intracellular replication in
each cell type, similar to LVSripA. Each mutant was also tested
for the ability to induce IL-1 secretion, as measured by ELISA in
supernatants from infected BMMs (Fig. 3C). Similar to what was
seen with LVSripA, LVS ripAaa4-47 and LVS ripAaa105-151
both induced increased levels of IL-1 in infected BMMs. To ver-
ify that each protein was expressed in the proper location, cyto-
plasmic membrane fractions of each mutant were analyzed via
Western blot assay using antibodies against RipAaa1-19 or
RipAaa112-128 (Fig. 3D). Deletion of amino acids 4 to 47 and 105
to 151 resulted in RipA proteins that are expressed in the correct
location, though at a slightly lower level. It is unlikely that the
reduced amount of membrane-associated protein was solely re-
sponsible for the mutant phenotypes since we found no direct
correlation between RipA protein expression levels and intracel-
lular growth (see Fig. S1 in the supplemental material). Finally, to
determine the role of each domain in the ability of RipA to
oligomerize, we performed in vivo cross-linking with formalde-
hyde or DSP as described above, excluding the first deletion mu-
tant, whose protein expression was too low to detect any cross-
linking (Fig. 3E). Unlike LVS, which again displayed several
higher-molecular-mass complexes, no RipA oligomer formation
was observed for LVS ripAaa105-151, suggesting that the second
cytoplasmic domain is required for binding. Together, these data
suggest that both cytoplasmic domains, corresponding to amino
acids 4 to 47 and 105 to 151, are required for RipA function and
that at least the second cytoplasmic domain is required for RipA
oligomerization.
At least four amino acids within RipA are required for intra-
cellular replication and suppression of the proinflammatory re-
sponse. Analysis of the results from a BLASTp search using the
protein sequence of RipA revealed a relatively short list of RipA-
like proteins that have E values below zero. Moreover, these pro-
teins are found only in individual strains of a given species, which
seem to be randomly distributed across prokaryotes (see Table S1
in the supplemental material). Thirteen amino acids are identical
or highly conserved among the 15 RipA-like proteins with E values
of less than 103. As an additional approach to identifying regions
required for RipA function, mutants expressing alanine substitu-
tions were made at each of these 13 conserved amino acids found
among the RipA-like proteins discussed above, as well as the single
cysteine, totaling 14 amino acid substitution mutants. Site-
directed mutagenesis was performed on a plasmid containing
ripA, and the mutated plasmid was transformed into LVSripA.
Each mutant was screened for expression of RipA in the cytoplas-
FIG 2 In vivo protein cross-linking of RipA. (A) Western blot assay of LVS lysates probed with anti-RipAaa1-19 antibody after SDS-PAGE under nonreducing
conditions (no ME; left lane) and under reducing conditions (right lane). (B) LVS treatment with either 0.5 mM DSP or 0.5% formaldehyde (Form.) and
analysis by Western blot assay using anti-RipAaa1-19 antibody. Incubation of samples at 100°C (formaldehyde) or addition of ME (DSP) cleaved selected
samples, as shown at the bottom. (C) LVS (lanes 1 to 3), LVS with plasmid-expressed RipA-HA (lanes 4 to 6), and LVS with chromosomally expressed RipA-HA
plus plasmid-expressed wild-type RipA (lanes 7 to 9) were grown overnight, incubated with 0.5% formaldehyde, and analyzed by Western blot assay probed with
anti-RipAaa1-19 (red) and anti-HA (green) antibodies. Lanes: 1, 4, and 7, untreated; 2, 5, and 8, 0.5% formaldehyde; 3, 6, and 9, 0.5% formaldehyde plus 100°C.
The images below each panel of the Western blot are cropped and enlarged from the Western blot to focus on the bands of interest. Although from the same blot,
the panel containing lanes 7 to 9 was exposed at a lower intensity in the red channel in order to distinguish the fainter upper band (green channel), and this results
in the upper band appearing more green than the expected yellow, as shown in lanes 4 to 6. All of the data shown are representative of at least three experiments.
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mic membrane using the anti-RipAaa1-19 antibody via Western
blot assay of lysates of cytoplasmic membrane fractions (Fig. 4A).
To determine whether any mutant could trans complement
LVSripA, each strain was analyzed for the ability to replicate
intracellularly in J774A.1 macrophages (Fig. 4B) or TC-1 epithe-
lial cells (Fig. 4C) and for induction of IL-1 secretion by infected
BMMs (Fig. 4D). The S46A, R48A, R49A, N53A, F55A, N60A,
C97A, and E134A mutants trans complemented LVSripA in all
of the assays, suggesting that none of these residues are required
for RipA function. Of the remaining mutants, the W100A and
P154A mutants had variable or intermediate phenotypes; how-
ever, the Y35A, K114A, E122A, and E150A mutants did not trans
complement LVSripA in any of the assays. Thus, at least these
four respective amino acids, Y35, K114, E122, and E150, are re-
FIG 3 Characterization of two RipA cytoplasmic domain deletion mutants. (A) Intracellular replication of wild-type LVS, LVSripA, LVS ripAaa4-47, and LVS
ripAaa105-151 was assessed within J774A.1 macrophages (A) and TC-1 epithelial cells (B) by gentamicin protection assay. Each graph is representative of one
of three experiments, each performed in triplicate, and the error bars show the standard deviations of triplicates. (C) Secretion of IL-1 by BMMs at 24 h
measured by ELISA in supernatants of cells left untreated or incubated with LVS, LVSripA, LVS ripAaa4-47, or LVS ripAaa105-151. The graph shows the
results of one of at least three experiments performed in triplicate, with error bars representing the standard deviations of replicates. (D) Protein expression of
LVS, LVSripA, LVS ripAaa4-47, and LVS ripAaa105-151 in LVS cytoplasmic membrane fractions was determined by Western blot assay probed with
anti-RipAaa112-128 for LVS ripAaa4-47 (top) or anti-RipAaa1-19 antibody for LVS ripAaa105-151 (bottom). (E) In vivo cross-linking on wild-type LVS
(lanes 1 to 5) and LVS ripAaa105-151 (lanes 6 to 10) was performed by treatment with 0.5% formaldehyde or 0.5 mM DSP. For some samples, cleavage was
achieved by the addition of ME (DSP) or incubation at 100°C (formaldehyde [Form.]), as shown at the bottom. Cross-linking was followed by Western blot
assay probed with anti-RipAaa1-19 antibody. The Western blots shown are representative of at least three experiments. Statistical significance was determined by
comparing the values for each respective mutant to the values for LVS. *, P  0.05; **, P  0.01; ***, P  0.001.
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quired for RipA function, and this corroborates the finding ob-
tained with the domain deletion mutants that both cytoplasmic
domains are required for RipA function.
Conservative and charge reversal amino acid changes con-
firm a role for K114, E122, and E150 in RipA function. Due to
their location in the second cytoplasmic domain and to further
investigate the importance of K114, E122, and E150 for RipA
function, both conservative and charge reversal substitutions were
made at each amino acid. The substitution mutations were again
generated using site-directed mutagenesis, and the mutants were
assessed for intracellular replication (Fig. 5A and B) and induction
of IL-1 secretion (Fig. 5C). For conservative changes E122D and
FIG 4 Characterization of RipA alanine substitution mutants for intracellular replication and suppression of the proinflammatory response. (A) The 14 RipA
alanine substitution mutants were expressed in LVSripA and analyzed for protein expression in the cytoplasmic membrane fractions of LVS by Western blot
assay probed with anti-RipAaa1-19 antibody. Each mutant was assessed for intracellular replication in J774A.1 macrophages (B) and TC-1 epithelial cells (C) by
gentamicin protection assay. The graphs represent consolidated data for each mutant from a representative of at least two experiments performed in triplicate,
and the error bars show the standard deviations of triplicates. (D) Each mutant was analyzed for induction of IL-1 secretion by infected BMMs at 24 h by ELISA.
The graph represents consolidated data for each mutant from a representative of at least two experiments performed in duplicate or triplicate, and the error bars
show standard deviations of replicates. Statistical significance was determined by comparing the values for each respective mutant to the values for LVSripA 
ripA since this strain has the backbone plasmid on which the mutants were made. *, P  0.05; ***, P  0.001.
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E150D, each mutant trans complemented the LVSripA pheno-
type, whereas the respective charge reversal substitution E122R
and E150R mutants did not. These data not only confirm a role for
E122 and E150 in RipA function, they suggest that the charge at
these sites is also important. With the conservative change K114R
mutant, an intermediate phenotype, or partial trans complemen-
tation, was observed. With the charge reversal K114E mutant, no
trans complementation was observed. Based on these data, we
conclude that K114 is important for RipA function but cannot
determine whether the charge is responsible for its function. To
verify that each mutant was expressed in the cytoplasmic mem-
brane, protein expression was determined via membrane frac-
tionations and Western blot assay using anti-RipAaa1-19 anti-
body as described above (Fig. 5D). Lastly, cross-linking
experiments were performed with the K114A, E122A, and E150A
mutants to determine whether any of these amino acids is re-
quired for RipA oligomerization (Fig. 5E and 6D). Interestingly,
each mutant was still able to form RipA oligomers, suggesting
either that these amino acids are not involved in oligomerization
or that there are multiple amino acids that mediating binding,
such that changing one amino acid is not sufficient to eliminate
the interaction.
Identification of an intragenic suppressor mutant supports a
role for the first cytoplasmic domain in RipA function. During
the course of experiments with the alanine substitution mutants,
the plasmids from LVS were repeatedly sequenced to verify the
integrity of the ripA sequence and the desired mutations within
RipA. In this process for K114A, E122A, and E150A, we frequently
observed mutations that resulted in a frameshift, loss of the ala-
nine substitution mutation (rare), or single amino acid changes
within ripA. Due to the relatively high frequency of mutations
found within RipA-E150A, one of the single amino acid changes
FIG 5 Further analysis of the importance of amino acids K114, E122, and E150 in RipA function. The charge reversal and conservative amino acid substitution
mutants for K114, E122, and E150 were assessed for intracellular replication within TC-1 cells (A) and J774A.1 macrophages (B) by gentamicin protection assays.
The graphs represent consolidated data for each mutant from a representative of at least two experiments performed in triplicate, and the error bars show
standard deviations of triplicates. (C) Each mutant was analyzed for induction of IL-1 secretion by BMMs at 24 h by ELISA in supernatants of infected cells. The
graph represents consolidated data for each mutant from a representative of at least two experiments performed in duplicate or triplicate, and the error bars show
standard deviations of replicates. (D) Each mutant was assessed for protein expression in the cytoplasmic membrane fraction of LVS by Western blot analysis
probed with anti-RipAaa1-19 antibody. (E) Wild-type LVS and the K114A and E122A mutants were cross-linked with 0.5% formaldehyde (Form.) and analyzed
by Western blot assay probed with anti-RipAaa1-19 antibody. Statistical significance was determined by comparing values for each respective mutant to the
values for LVSripA  ripA. **, P  0.01; ***, P  0.001.
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identified was selected for further characterization, i.e., E150A
with an additional V39A change, which was designated E150A/
V39A. Assays for intracellular replication (Fig. 6A and B) and also
for IL-1 secretion (Fig. 6C) revealed that this mutant trans com-
plemented LVSripA, suggesting that this new mutation was an
intragenic suppressor. To confirm that the phenotype was the re-
sult of the intragenic mutation and not the result of an extragenic
mutation, the plasmid containing RipA E150A/V39A was isolated
and retransformed into LVSripA three independent times. Each
of these new E150A/V39A transformants was assayed for intracel-
lular replication and for IL-1 secretion and displayed the same
phenotype as the original suppressor mutant, confirming that the
V39A substitution was responsible for trans complementation.
After formaldehyde cross-linking, the E150A/V39A mutant also
displayed the same higher-molecular-mass bands as the wild type
and the E150A mutant, suggesting that this trans complementa-
tion was not a result of altered oligomeric complex formation (Fig.
6D). Of note, a mutant containing only the V39A substitution in
the LVSripA deletion background did not display a defect in
intracellular replication (data not shown). Overall, when consid-
ering the intragenic suppressor data, one can infer that the two
cytoplasmic domains may be interacting with each other or alter-
natively with another protein or molecule.
DISCUSSION
F. tularensis is a highly successful pathogen; however, many of the
known virulence factors still have no identified function. RipA is a
virulence factor that was previously shown to be required in vivo in
a pulmonary mouse model of tularemia, likely in part due to its
inability to suppress the proinflammatory response like wild-type
F. tularensis LVS or Schu S4 (17, 22; unpublished observations).
Furthermore, RipA is required for F. tularensis intracellular repli-
cation in both macrophages and epithelial cells (17). However,
LVSripA escapes the phagosome with kinetics similar to those of
wild-type F. tularensis (17). This phenotype suggests that a lack of
RipA results in a strain unable to adapt to the environment of the
host cell cytoplasm. Not surprisingly, LVSripA grows poorly in
vitro at higher pHs and the expression of both the ripA transcript
and the RipA protein is upregulated at higher pHs and between 1
and 6 h postinfection of host cells, all correlating with a role for
RipA in adaptation to the cytoplasm (16).
This study addressed the question of RipA function at the bio-
chemical and molecular levels. Preceding studies demonstrated
FIG 6 Identification and characterization of an intragenic suppressor muta-
tion in RipA E150A. A spontaneous V39A suppressor mutation appeared in
the E150A mutant (E150A/V39A), and this plasmid was used to retransform
three LVSripA strains and generate E150A/V39A-R1, -R2, and -R3. Wild-
type LVS, LVSripA, LVSripA  ripA, the E150A mutant, the E150A/V39A
mutant, and the E150A/V39AR1-3 mutant were assessed for intracellular rep-
lication within J774A.1 macrophages (A) and TC-1 epithelial cells (B) by gen-
tamicin protection assay. The graphs represent consolidated data for each
mutant from a representative of at least two experiments performed in tripli-
cate, and the error bars show standard deviations of triplicates. (C) Secretion of
IL-1 by macrophages at 24 h as measured by ELISA in supernatants of in-
fected cells. The graph shows a representative of at least two experiments per-
formed in duplicate or triplicate, and the error bars show standard deviations
of replicates. (D) Wild-type LVS, the E150A mutant, and the E150A/V39A
mutant were cross-linked using 0.5% formaldehyde (Form.) and analyzed by
Western blot assay probed with anti-RipAaa1-19 antibody. The Western blot
shown is representative of at least two experiments. Statistical significance was
determined by comparing the values for each respective mutant to the values
for LVSripA  ripA. *, P  0.05; ***, P  0.001.
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that RipA localizes to the cytoplasmic membrane of F. tularensis
(17). Here, the topology of RipA within the cytoplasmic mem-
brane was determined in terms of orientation and subcellular lo-
cation of functional domains. RipA has three transmembrane
domains, two large cytoplasmic domains, and two smaller
periplasmic domains with the N terminus in the cytoplasm and
the C terminus in the periplasm. Additionally, RipA was shown to
form homoligomers in the membrane by using in vivo cross-
linking with either formaldehyde or DSP, and even in the absence
of protein cross-linkers, the protein can exist in higher-order
forms. The first of several higher-molecular-mass bands appears
to correspond to at least a dimer size (40 kDa), suggesting that
RipA forms a homodimer. RipA homodimerization was con-
firmed by experiments using strains expressing both RipA and
RipA-HA where, in place of the single 40-kDa band, there were
three bands corresponding to RipA-RipA dimers, RipA–RipA-HA
dimers, and RipA-HA–RipA-HA dimers. Due to the lack of reso-
lution of the higher-molecular-mass bands in these experiments
and since these bands are not exactly trimer, tetramer, etc. in size,
we cannot definitively say whether or not these bands are solely
RipA or RipA cross-linked to another protein; however, based on
the characteristic banding pattern, we suspect that these forms
represent homoligomers as well. We are in the process of deter-
mining whether or not RipA interacts with any other F. tularensis
proteins. Further insight into RipA topology, structure, and ulti-
mately function could be gained by doing biochemical experi-
ments such as size exclusion chromatography and solving the
crystal structure.
Francisella RipA proteins and some of the other RipA-like pro-
teins have only a single cysteine found in the second transmem-
brane domain, which is uncommon. The highly reactive thiol
group of a cysteine is known to be involved in several biological
functions, most prominently the formation of disulfide bonds
with other cysteine residues. These disulfide bonds can occur
within the same protein to maintain tertiary structure or with a
cysteine from another protein to mediate intermolecular complex
formation, making unpaired cysteines quite rare. Due to the high
reactivity of the thiol group, cysteine is not usually found in iso-
lation, and proteins with a single cysteine form oligomers or bind
metals or other molecules via this amino acid. The facts that the
RipA C97A mutant still formed oligomers (data not shown), was
not attenuated for intracellular growth, and did not induce IL-1
secretion by infected macrophages suggest that this is not the case
for RipA. Thus, the role of this single cysteine in RipA function
remains unknown. One explanation is that there is no specific role
for C97 in RipA function, especially considering that the cysteine
is not completely conserved in all RipA-like proteins and that in
some RipA-like proteins there is more than one cysteine present.
Alternatively, the cysteine has a function unique to only Franci-
sella RipA or a subset of RipA-like proteins. An interesting possi-
bility is that the cysteine is involved in conformational changes in
the RipA protein or binds to a small molecule, as opposed to
directly binding to protein partners.
Employing the topology model of RipA, we targeted specific
domains for assessment of their roles in RipA function. Using
domain deletion mutants, we found that each cytoplasmic do-
main is required for RipA function in terms of intracellular repli-
cation in macrophages and epithelial cells and suppression of the
proinflammatory immune response and that at least the second
cytoplasmic domain is required for RipA oligomer formation.
This is further supported by analysis of mutants with Y35, K114,
E122, and E150 substitutions, each of which is within a cytoplas-
mic domain, which showed that these amino acids are also re-
quired for intracellular replication in both macrophages and epi-
thelial cells, as well as for suppression of the proinflammatory
immune response. Unlike the RipAaa105-151 cytoplasmic do-
main deletion mutant, the single amino acid changes were not
sufficient to prevent RipA oligomerization, suggesting that the
interactions are mediated by multiple amino acids or that the
individual amino acids are involved in some other aspect of RipA
function. In terms of the first cytoplasmic domain, the inability to
determine the involvement of amino acids 4 to 47 in RipA
oligomer formation was due to RipAaa4-47 decreased cytoplas-
mic membrane expression. Nevertheless, there is a possibility that
the first cytoplasmic domain is involved in the formation of RipA
oligomers and even that the two cytoplasmic domains interact.
The intragenic suppressor mutation V39A in the E150A mutant
restores the ability of the E150A mutant to replicate intracellularly
and suppress the IL-1 response. That V39 and E150 are in the
first and second cytoplasmic domains, respectively, suggests that
the two cytoplasmic domains interact with each other or, alterna-
tively, with another shared substrate. Overall, our data show that
both cytoplasmic domains, and even certain amino acids within
each domain, are important for RipA function.
The fact that there are other RipA-like proteins in a wide range
of mainly less-studied species, including pathogenic, nonpatho-
genic, Gram-positive, and Gram-negative mycobacteria; soil-
dwelling, marine-dwelling, and freshwater-dwelling bacteria; and
even one Archaea member is intriguing. Stranger still is the fact
that RipA proteins have been identified only in select strains of a
given species, with the exception being members of the genus
Francisella, where RipA is conserved among all sequenced species
and strains. This could be due in part to a lack of genome se-
quences for a given species, or RipA could be a truly rare protein or
one for which there are functional homologs that share little pro-
tein sequence homology. So far, RipA-like proteins have been
identified in only four strains of pathogenic bacterial species: My-
cobacterium avium, which can cause disease in birds, as well as
children, the elderly, and the immunocompromised; Streptomyces
scabiei, which causes disease in plants; Aeromonas caviae, which is
a cause of gastrointestinal disease in humans; and Actinomyces
odontolyticus, which is an opportunistic pathogen causing invasive
disease in elderly or immunocompromised patients with ad-
vanced dental cavities. Whether or not these RipA-like proteins
play a role in pathogenesis is not known. Since we know that RipA
is an important F. tularensis virulence factor, it is possible that the
function of RipA will represent a virulence mechanism that is
conserved among pathogenic bacteria. An alternative, and equally
exciting, possibility is that RipA functions as a novel virulence
mechanism unique to Francisella. Since the bacteria in which
other RipA-like proteins are found are so varied in classification, it
will be interesting to determine if there are differences in the func-
tion of RipA among pathogenic and nonpathogenic strains. The
fact that a virulence gene homolog is found in environmental
bacteria is not unprecedented. A recent in silico analysis of marine
bacterial genomes for virulence factors revealed an abundance of
well-characterized virulence genes, including pathogenicity is-
lands and genes encoding secretion systems and toxins, repre-
sented among the strains analyzed (32). Genes encoding virulence
factors are also widely distributed among soil bacteria (4). Perhaps
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RipA belongs to a novel family of proteins that will be revealed as
more strains are sequenced and deposited into NCBI, resulting
in the identification of more RipA-like proteins. Overall, determi-
nation of the function of RipA is relevant not only for understand-
ing the virulence of F. tularensis but also perhaps for understand-
ing the function of a potential class of proteins distributed
throughout the bacterial kingdom.
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